Stuttgart
28.11.25 | 07:41
0,051 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,048 | 0,061 | 18:47 | |
| 0,051 | 0,057 | 28.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Hemostemix Inc (2): Hemostemix to acquire two cardiology practices | 13 | Stockwatch | ||
| Mi | Hemostemix Inc.: Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two | 324 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first two... ► Artikel lesen | |
| 21.11. | Hemostemix Inc (2): Hemostemix's ACP-01 dementia trial to be led by Shankle | 1 | Stockwatch | ||
| 20.11. | Hemostemix Inc.: Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia | 168 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 18.11. | Hemostemix Inc.: Hemostemix Closes CDN$280,594 Private Placement | 376 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy... ► Artikel lesen | |
| 18.11. | Hemostemix Inc.: Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida | 322 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care Conference... ► Artikel lesen | |
| 13.11. | Hemostemix Inc.: Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway | 527 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced key highlights from its November 12, 2025 Grand Rounds presentation (to... ► Artikel lesen | |
| 05.11. | Hemostemix Inc (2): Hemostemix closes $461,230 first tranche of financing | 11 | Stockwatch | ||
| HEMOSTEMIX Aktie jetzt für 0€ handeln | |||||
| 04.11. | Hemostemix Inc.: Hemostemix Closes Private Placement of $461,230 | 365 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy... ► Artikel lesen | |
| 31.10. | Hemostemix Inc (2): Hemostemix talks work in Florida | 2 | Stockwatch | ||
| 30.10. | Hemostemix Inc.: Hemostemix's Boots on the Ground in Florida October Update | 378 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 28.10. | Hemostemix Inc.: Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI | 359 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 23.10. | Hemostemix Inc (2): Hemostemix receives Know Your Health trademark in Japan | 3 | Stockwatch | ||
| 22.10. | Hemostemix Inc.: Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42 | 328 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 16.10. | Hemostemix Inc (2): Hemostemix seeks to treat refractory angina | 3 | Stockwatch | ||
| 15.10. | Hemostemix Inc.: Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol | 329 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 10.10. | Hemostemix Inc (2): Hemostemix applies for vascular dementia study approval | 4 | Stockwatch | ||
| 09.10. | Hemostemix Inc.: Hemostemix Files for Ethics Approval of its Study of Vascular Dementia | 336 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its Institutional Review... ► Artikel lesen | |
| 08.10. | Hemostemix Inc (2): Hemostemix receives $330,000 lead order for placement | 2 | Stockwatch | ||
| 07.10. | Hemostemix Inc.: Hemostemix's Insider Lead Order of $330,000 Private Placement | 314 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a lead order of $330,000 for a non brokered... ► Artikel lesen |
1 2 3 4 5 Weiter >>
98 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,800 | -0,24 % | Kaufempfehlung und Großauftrag: Evotec, Nordex, Desert Gold | Sind über 100 % Kursgewinn bei der Nordex-Aktie noch nicht genug? Dies glauben jedenfalls Analysten. Zudem hat der Windturbinenhersteller auch noch einen Großauftrag an Land gezogen. Geht die Rally... ► Artikel lesen | |
| QIAGEN | 41,125 | -0,77 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| VALNEVA | 3,998 | +0,50 % | Valneva veröffentlicht finale Phase-2-Studiendaten für Borreliose-Impfstoff | Der französische Impfstoffhersteller Valneva hat finale Daten aus der Phase-2-Studie VLA15-221 für seinen Lyme-Borreliose-Impfstoffkandidaten VLA15 vorgelegt. Die Ergebnisse zeigen, dass die Antikörperwerte... ► Artikel lesen | |
| EPIGENOMICS | 0,870 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,087 | +0,40 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 319,00 | -0,31 % | Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems? | ||
| CRISPR THERAPEUTICS | 46,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| OCUGEN | 1,082 | +1,64 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,70 | +0,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PASITHEA THERAPEUTICS | 1,470 | +52,33 % | Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise | ||
| ARCELLX | 72,71 | -0,74 % | CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting | ||
| ADMA BIOLOGICS | 19,180 | +0,21 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 195,96 | +3,94 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| DYNE THERAPEUTICS | 21,910 | +3,50 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an |
Das Unternehmen HEMOSTEMIX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,051 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOSTEMIX INC finden Sie auf Wallstreet Online.